Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multidrug resistance (MDR) is a significant challenge in cancer therapy, involving drug transporters and complex cellular signaling pathways.
• Nitric oxide (NO) donors are emerging as potential anticancer agents due to their ability to address these complexities.
• Previous research demonstrated the efficacy of furoxan-based NO-releasing compounds against tumors.

Purpose of the Study:

• To evaluate the efficacy of DDB-nitric oxide, a novel bifendate derivative, against sensitive and MDR tumor cells.
• To elucidate the mechanism of action of DDB-nitric oxide in MDR cancer cells.
• To assess the role of nitric oxide release in the compound's cytotoxicity.

Main Methods:

• Synthesis of a bifendate-nitric oxide derivative (DDB-nitric oxide).
• Assessment of cell viability in sensitive and MDR tumor cell lines.
• Analysis of ABC transporter function and expression.
• Investigation of signaling pathways including HIF-1α, AKT, ERK, and NF-κB.
• Evaluation of mitochondrial tyrosine nitration and apoptosis induction.
• Use of nitric oxide scavengers to confirm NO-mediated effects.

Main Results:

• DDB-nitric oxide effectively inhibited viability in both sensitive and MDR tumor cells at low concentrations.
• The compound's potency was independent of major ABC transporter inhibition.
• Mechanisms involved mitochondrial tyrosine nitration, apoptosis induction, and downregulation of HIF-1α, AKT, ERK, and NF-κB signaling in MDR cells.
• Nitric oxide scavenging significantly reduced DDB-nitric oxide's cytotoxic effects, confirming NO release as the primary driver.

Conclusions:

• DDB-nitric oxide is a potent anticancer agent against MDR tumors, acting through NO-mediated mechanisms.
• Its efficacy is independent of major drug efflux pumps, suggesting a novel therapeutic approach.
• The compound's ability to overcome MDR and the reported difficulty in developing resistance to NO donors position it as a promising candidate for MDR cancer treatment.